tbuckley/cabot-search huggingface dataset:
Incisional Negative Pressure Wound Therapy Following Surgical Repair of Lower Extremity Fractures
Authors: Carmen E. Quatman, Michael E. Villarreal, Amalia Cochran
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
Authors: Stephan Windecker, Azeem Latib, Elvin Kedhi, Ajay J. Kirtane, David E. Kandzari, Roxana Mehran, Matthew J. Price, Alexandre Abizaid, Daniel I. Simon, Stephen G. Worthley, Azfar Zaman, Martin Hudec, Petra Poliacikova, A. Kahar bin Abdul Ghapar, Kamaraj Selvaraj, Ivo Petrov, Darren Mylotte, Eduardo Pinar, Raul Moreno, Franco Fabbiocchi, Sanjeevan Pasupati, Hyo-Soo Kim, Adel Aminian, Charles Tie, Adrian Wlodarczak, Seung-Ho Hur, Steven O. Marx, Ivana Jankovic, Sandeep Brar, Lisa Bousquette, Minglei Liu, Gregg W. Stone
Journal: New England Journal of Medicine (2020)

Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited.In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year. The principal secondary outcome was target-lesion failure, an effectiveness composite of death from cardiac causes, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. Both outcomes were powered for noninferiority.A total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drug-coated stents (993 patients). At 1 year, the primary outcome was observed in 169 of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 (16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; noninferiority margin, 4.4; P = 0.007 for noninferiority).Among patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes. (Funded by Medtronic; ONYX ONE ClinicalTrials.gov number, NCT03344653.).
Behavioral Economic Insights for Pediatric Obesity
Authors: Heather R. Frank, Peter A. Ubel, Charlene A. Wong
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Hepatitis D virus in Uzbekistan
Authors: Malika Khodjaeva, Nargiz Ibadullaeva, Aziza Khikmatullaeva, Elizaveta Joldasova, Sharapov Said, Ahmedova Shahnoza, Umed Ismoilov, Gian Paolo Caviglia, Mario Rizzetto, Erkin Musabaev
Journal: The Lancet. Gastroenterology & hepatology (2020)
Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma
Authors: Peter B. Dirks, Mark R. Gilbert, Eric C. Holland, Elizabeth A. Maher, William A. Weiss
Journal: Clinical Cancer Research (2020)

Abstract Members of the scientific and clinical neuro-oncology community met in April 2019 to discuss the current challenges and opportunities associated with translating basic science discoveries in glioblastoma for improved survival of patients. A summary of key points of these discussions is presented in this article.
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
Authors: Camus Nimmo, James Millard, Kayleen Brien, Sashen Moodley, Lucy van Dorp, Keeren Lutchminarain, Allison Wolf, Alison D. Grant, Francois Balloux, Alexander S. Pym, Nesri Padayatchi, Max O'Donnell
Journal: European Respiratory Journal (2020)

<b>Genetic mutations linked to bedaquiline resistance were found before starting treatment and acquired during treatment in patients with drug-resistant TB and HIV in KwaZulu-Natal, South Africa. Routine bedaquiline resistance testing needs to be accelerated.</b>http://bit.ly/2vnL4VY
A Treatment-Refractory, Perianal Tumor Arising in an Otherwise Healthy Older Adult Woman
Authors: Erika L. Hagstrom, Dylan Haynes, Alex G. Ortega-Loayza
Journal: JAMA Dermatology (2020)

A woman in her 80s presented with a growing, painful tumor on her buttock with epithelial hyperplasia, ulceration, focal multinucleated keratinocytes, and herpes simplex virus positivity. What is your diagnosis?
Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy
Authors: Jiang-Ping Song, Liang Chen, Xiao Chen, Jie Ren, Ning-Ning Zhang, Tiara Tirasawasdichai, Zhen-Liang Hu, Wei Hua, Yi-Ran Hu, Hui-Ru Tang, Huei-Sheng Vincent Chen, Sheng-Shou Hu
Journal: Science Translational Medicine (2020)

Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy.
Opportunities and Challenges for Polygenic Risk Scores in Prognostication and Prevention of Cardiovascular Disease
Authors: Christopher J. O’Donnell
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Application of Basic Epidemiologic Principles and Electronic Health Records in a Deep Learning Prediction Model
Authors: Soo Ick Cho, Dongheon Lee, Seong Jin Jo
Journal: JAMA Dermatology (2020)

To the Editor We found the study by Wang et al1 to be an interesting read. It raises important issues regarding the data-driven approach in the field of dermatology, and some obstacles should be discussed before applying it clinically.
Abstract 15996: Hospital Readmissions Reduction Program: Decrease in Heart Failure Readmissions and Mortality
Authors: Malik Bilal Ahmed, Anshul Parulkar, Wasiq Sheikh, Sanchita Singal Parulkar, Esseim Sharma, Brian D McCauley, Lauren Rousseau, Antony F Chu
Journal: Circulation (2019)

Introduction: Medicare analyses have questioned the efficacy of the Hospital Readmissions Reduction Program (HRRP). We sought to adress this question via large national datasets. Hypothesis: When a...
Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii
Authors: N.M. Smith, J.R. Lenhard, K.R. Boissonneault, C.B. Landersdorfer, J.B. Bulitta, P.N. Holden, A. Forrest, R.L. Nation, J. Li, B.T. Tsuji
Journal: Clinical Microbiology and Infection (2020)
Randomized Clinical Trials of Artificial Intelligence
Authors: Derek C. Angus
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Artificial Intelligence Improves Breast Cancer Screening in Study
Authors: Jennifer Abbasi
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What is the real role of ultrasound in the management of juvenile idiopathic arthritis?
Authors: Rolando Cimaz, Teresa Giani, Roberto Caporali
Journal: Annals of the Rheumatic Diseases (2020)

The use of musculoskeletal ultrasonography (US) in the management of rheumatoid arthritis (RA) has drawn attention to paediatric rheumatologists, and this has become an important part of the clinical care of patients with juvenile idiopathic arthritis (JIA) as well. However, several points have to be addressed before drawing conclusions on the usefulness in the everyday clinical management of JIA.

First, even in RA a similar viewpoint1 argued against the use of US for directing treatment decisions. In fact, many pitfalls have been highlighted by the authors, including the meaning of grey scale and/or power Doppler signal as sign of active inflammation versus past synovitis, the presence of abnormal US findings in a sizeable percentage of healthy subjects, the technical differences between different machines and the lack of standardisation. Indeed, the authors pointed out that in prospective therapeutic clinical trials with a Treat to Target (T2T) strategy following patients with US was not needed.

If we go to square one, it needs to be emphasised that in a growing skeleton the imaging results can be quite different than in adults. In fact, in children physiological US findings might be misinterpreted as pathologic. Skeletal maturation has a profound effect on imaging results, since bone, cartilage and adjacent structures undergo continuous modifications with growth. Normal US appearance of paediatric joints should be the starting point for any subsequent definition of pathology, and in particular for studies in JIA.

In order to standardise the use of US in paediatric rheumatology, definitions for US findings in the different parts of the normal paediatric joint have been developed and validated through Delphi process in different publications.2 3 A systematic standardised examination method was proposed, and an atlas of images of normal joint appearance at different ages has accordingly been created. Subsequently, the Outcome Measures …
T-cell senescence accelerates angiotensin II-induced target organ damage
Authors: Xiao-Xi Pan, Fang Wu, Xiao-Hui Chen, Dong-Rui Chen, Hong-Jin Chen, Ling-Ran Kong, Cheng-Chao Ruan, Ping-Jin Gao
Journal: Cardiovascular Research (2020)

Abstract Aims Aging is a risk factor for cardiovascular diseases and adaptive immunity has been implicated in angiotensin (Ang) II-induced target organ dysfunction. Herein, we sought to determine the role of T-cell senescence in Ang II-induced target organ impairment and to explore the underlying mechanisms. Methods and results Flow cytometric analysis revealed that T cell derived from aged mice exhibited immunosenescence. Adoptive transfer of aged T cells to immunodeficient RAG1 KO mice accelerates Ang II-induced cardiovascular and renal fibrosis compared with young T-cell transfer. Aged T cells also promote inflammatory factor expression and superoxide production in these target organs. In vivo and in vitro studies revealed that Ang II promotes interferon-gamma (IFN-γ) production in the aged T cells comparing to young T cells. Importantly, transfer of senescent T cell that IFN-γ KO mitigates the impairment. Aged T-cell-conditioned medium stimulates inflammatory factor expression and oxidative stress in Ang II-treated renal epithelial cells compared with young T cells, and these effects of aged T-cell-conditioned medium are blunted after IFN-γ-neutralizing antibody pre-treatment. Conclusion These results provide a significant insight into the contribution of senescent T cells to Ang II-induced cardiovascular dysfunction and provide an attractive possibility that targeting T cell specifically might be a potential strategy to treat elderly hypertensive patients with end-organ dysfunction.
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Authors: Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker, Erin Hertlein, John C. Byrd
Journal: Journal of Hematology & Oncology (2020)

Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) including Src and Lyn, spleen tyrosine kinase (SYK), and bruton's tyrosine kinase (BTK). Recently, the multi-kinase inhibitor ArQule 531 (ARQ 531) has demonstrated potent inhibition of SFK and BTK that translated to improved pre-clinical in vivo activity as compared with the irreversible BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) models. Given the superior activity of ARQ 531 in CLL, and recognition that this molecule has a broad kinase inhibition profile, we pursued its application in pre-clinical models of AML. The potency of ARQ 531 was examined in vitro using FLT3 wild type and mutated (ITD) AML cell lines and primary samples. The modulation of pro-survival kinases following ARQ 531 treatment was determined using AML cell lines. The effect of SYK expression on ARQ 531 potency was evaluated using a SYK overexpressing cell line (Ba/F3 murine cells) constitutively expressing FLT3-ITD. Finally, the in vivo activity of ARQ 531 was evaluated using MOLM-13 disseminated xenograft model. Our data demonstrate that ARQ 531 treatment has anti-proliferative activity in vitro and impairs colony formation in AML cell lines and primary AML cells independent of the presence of a FLT3 ITD mutation. We demonstrate decreased phosphorylation of oncogenic kinases targeted by ARQ 531, including SFK (Tyr416), BTK, and fms-related tyrosine kinase 3 (FLT3), ultimately leading to changes in down-stream targets including SYK, STAT5a, and ERK1/2. Based upon in vitro drug synergy data, we examined ARQ 531 in the MOLM-13 AML xenograft model alone and in combination with venetoclax. Despite ARQ 531 having a less favorable pharmacokinetics profile in rodents, we demonstrate modest single agent in vivo activity and synergy with venetoclax. Our data support consideration of the application of ARQ 531 in combination trials for AML targeting higher drug concentrations in vivo.
Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.
Authors: Alex Martinez Marti, Pablo Martinez, Claudia Aura, Susana Cedres, Ivana Sullivan, Jose Jimenez, Ludmila Prudkin, Maria Angeles Montero, Nuria Murtra-Garrell, Esther Zamora, Alejandro Navarro, Javier Hernandez-Losa, Maite Salcedo, Mercedes Canela, Santiago Ramon y Cajal, Josep Tabernero, Enriqueta Felip
Journal: Journal of Clinical Oncology (2012)

7041 Background: The FGFR1 gene is located in the chromosomal region 8p12 and encodes a transmembrane receptor tyrosine kinase. Amplification of FGFR1 has been reported in lung cancer, predominantly in SCC (in up to ~ 20%) and has been considered a potential target for treatment with anti-FGFR1 agents. Different methods and cutoff levels to determine FGFR1 amplification have been reported but as yet no consensus has been reached on standard method. The aim of this study is to assess FGFR1 amplification determined by FISH analysis in a set of samples from 101SCC pts and to explore their clinical features. Methods: Tumor samples from 101SCC pts diagnosed at our institution from August 2007 to August 2011 were screened for FGFR1 amplification by FISH using the ZytoLight SPEC FGFR1/CEN8 probe. FGFR1 was considered FISH positive with a ratio &gt; 2.2 and FISH FGFR1 was polysomic with 3 or more signals in ≥30% of tumor cells, any other result was considered as negative. For exploratory analyses FGFR1 amplification was considered positive if a median of 6 or more gene copies were identified and FISH were polysomic with more than 2 gene copies but less than 6. Results: Pts characteristics: median age 76 yrs (range 45-80), 91% male, 33% current smokers, 67% former smokers, stage: 8% IA/ 15% IB/ 11% IIA/ 11% IIB/ 24% IIIA, 12% IIIB/ 19% IV. With a median follow up of 48 months, the median overall survival was 18 months. FISH FGFR1 was positive (ratio &gt; 2.2) in 7 (6.9%) pts: 6 were male, 4 former smokers. FISH FGFR1 was considered negative but polysomic (3 or more signals in ≥30% of tumor cells) in 43/94 (45%) pts. If we use for FISH positivity a cutoff of 6 or more copies only 3 patients were considered as positive for FGFR1 amplification (2 were also FISH positive by ratio&gt;2.2). All those 5 patients considered FISH negative by gen copy number (but positive by ratio) were polysomic. Conclusions: In our experience FGFR1 amplification detected by FISH isrelatively uncommon in SCC, although a relevant proportion of FGFR1 FISH negative tumors had polysomy. Standarization of methods to determine FGFR1 amplification and the potential clinical significance of the presence of FGFR1 polysomy are needed.
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center
Authors: Lukasz Kwapisz, Laura E. Raffals, David H. Bruining, Darrell S. Pardi, William J. Tremaine, Sunanda V. Kane, Konstantinos A. Papadakis, Nayantara Coelho-Prabhu, John B. Kisiel, Valerie Heron, William A. Faubion, Edward V. Loftus
Journal: Clinical Gastroenterology and Hepatology (2020)